Production (Stage)
Moleculin Biotech, Inc.
MBRX
$0.67
-$0.0201-2.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.51% | -4.22% | -17.57% | -17.17% | -9.25% |
| Depreciation & Amortization | -3.13% | -11.43% | -3.13% | 0.00% | 6.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.99% | -25.52% | 19.98% | -3.53% | -20.07% |
| Operating Income | 10.99% | 25.52% | -19.98% | 3.53% | 20.07% |
| Income Before Tax | -29.50% | 81.67% | -88.84% | 27.73% | 37.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.50% | 81.67% | -88.84% | 27.73% | 37.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.50% | 81.67% | -88.84% | 27.73% | 37.21% |
| EBIT | 10.99% | 25.52% | -19.98% | 3.53% | 20.07% |
| EBITDA | 11.03% | 25.57% | -20.06% | 3.54% | 20.17% |
| EPS Basic | 65.82% | 92.66% | -1.04% | 43.76% | 51.20% |
| Normalized Basic EPS | 65.82% | 92.66% | -1.04% | 43.75% | 51.20% |
| EPS Diluted | 65.82% | 92.66% | -1.04% | 43.76% | 51.20% |
| Normalized Diluted EPS | 65.82% | 92.66% | -1.04% | 43.75% | 51.20% |
| Average Basic Shares Outstanding | 278.87% | 149.67% | 86.90% | 28.49% | 28.67% |
| Average Diluted Shares Outstanding | 278.87% | 149.67% | 86.90% | 28.49% | 28.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |